Australia · Delayed Price · Currency is AUD Invion Company Description
Invion Limited, an Australian clinical-stage life sciences enterprise, is actively engaged in the research and development of photodynamic therapy (PDT) to address various cancer types.
Its flagship offering, IVX-PDT, is a photosensitizer agent being developed to combat skin cancers alongside a range of solid tumors, including those affecting the lungs, prostate, ovaries, and mesothelioma.
The company has forged a research and development alliance with the Hudson Institute of Medical Research, jointly pursuing R&D initiatives for its Photosoft technology across a broad spectrum of cancer treatments.
Moreover, a dedicated research agreement with the Peter MacCallum Cancer Centre facilitates pre-clinical and in-vitro investigations into Invion's IVX-PDT for ano-genital cancers, such as penile and anal cancers.
The firm was established in 2000 and is headquartered in Melbourne, Australia.
| Country | Australia |
| Founded | 2000 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| CEO | Thian Chew |
Contact Details
Address: 385 Bourke Street Melbourne, VIC VIC Australia | |
| Phone | 61 3 9692 7222 |
Stock Details
| Ticker Symbol | IVX |
| Exchange | Australian Securities Exchange |
| Fiscal Year | July - June |
| Reporting Currency | AUD |
| ISIN Number | AU000000IVX4 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Thian Chew | Executive Chairman and Chief Executive Officer |
| Melanie Jaye Leydin B.Bus, C.A. | Chief Financial Officer, Company Secretary and Non-Executive Director |
| Dr. Dean Naylor | Head of Intellectual Property Development |